Back to Search
Start Over
A polymeric paste-drug formulation for intratumoral treatment of prostate cancer.
- Source :
-
Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2020 Jun; Vol. 23 (2), pp. 324-332. Date of Electronic Publication: 2019 Nov 25. - Publication Year :
- 2020
-
Abstract
- Objective: Focal therapy has emerged as a treatment option for low- to intermediate-risk localized prostate cancer (PCa) patients, to balance the risks for urinary and sexual morbidity of radical treatment with the psychological burden of active surveillance. In this context, we developed ST-4PC, an injectable, polymeric paste formulation containing docetaxel (dtx) and bicalutamide (bic) for image-guided focal therapy of PCa. The objective of this work was to evaluate the in vitro characteristics and in vivo toxicity and efficacy of ST-4PC.<br />Material and Methods: In vitro drug release was evaluated using high-performance liquid chromatography. In vivo toxicity of blank- and drug-loaded ST-4PC was assessed in mice and rats. Tumor growth inhibition was evaluated in LNCaP subcutaneous (s.c.) and LNCaP-luc orthotopic xenograft models. Using the s.c. model, mice were monitored weekly for weight loss, tumor volume (TV) and serum PSA. For the orthotopic model, mice were additionally monitored for bioluminescence as measure of tumor growth.<br />Results: ST-4PC demonstrated a sustained and steady release of incorporated drugs with 50% dtx and 20% bic being released after 14 days. While no systemic toxicity was observed, dose-dependent local side effects from dtx developed in the s.c. but not in the orthotopic model, illustrating the limitations of s.c. models for evaluating local cytotoxic therapy. In the s.c. model, 0.1%/4% and 0.25%/4% dtx/bic ST-4PC paste significantly reduced PSA progression, but did not have a significant inhibitory effect on TV. ST-4PC loaded with 1%/4% dtx/bic significantly reduced TV, serum PSA, and bioluminescence in the orthotopic xenograft model. Compared with drugs dissolved in DMSO, ST-4PC significantly delayed tumor growth.<br />Conclusion: Image-guided focal therapy using ST-4PC demonstrated promising inhibition of PSA progression and orthotopic tumor growth in vivo without significant toxicity, and warrants further clinical evaluation.
- Subjects :
- Anilides administration & dosage
Animals
Antineoplastic Combined Chemotherapy Protocols chemistry
Antineoplastic Combined Chemotherapy Protocols pharmacokinetics
Apoptosis
Cell Proliferation
Docetaxel administration & dosage
Humans
Male
Mice
Nitriles administration & dosage
Prostatic Neoplasms metabolism
Prostatic Neoplasms pathology
Rats
Tissue Distribution
Tosyl Compounds administration & dosage
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Antineoplastic Combined Chemotherapy Protocols pharmacology
Drug Compounding methods
Polymers chemistry
Prostatic Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5608
- Volume :
- 23
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Prostate cancer and prostatic diseases
- Publication Type :
- Academic Journal
- Accession number :
- 31767941
- Full Text :
- https://doi.org/10.1038/s41391-019-0190-x